Overview

Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Horizon Pharma Ireland, Ltd., Dublin Ireland
Treatments:
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal